Author: admin

Experia Moving Expands Premium Moving Services to Greenwich, CT With Elite Team and VIP Experience

“At Experia Moving, we believe every move deserves precision, care, and a luxury-level experience. Greenwich families and businesses deserve nothing less.” – Nikola Radunovich, Founder of Experia Moving”
Experia Moving, known for elite relocation services in NYC, is now serving Greenwich, CT. With professionally trained crews, premium packing materials, and live truck tracking, Experia brings a VIP moving experience to families and businesses in Fairfield County.

Greenwich, CT – Aug 21, 2025 – Experia Moving, a trusted name in luxury relocation services in New York City, is proud to announce the expansion of its elite moving solutions to Greenwich, Connecticut. Known for professionalism, precision, and a VIP approach to moving, Experia Moving is bringing its signature service to families and businesses throughout Fairfield County.

Founded by industry veteran Nikola Radunovich, Experia Moving has built a reputation for exceeding expectations in one of the most competitive moving markets in the United States. What sets the company apart is its Movers Academy, a proprietary training system that prepares every team member for excellence. Within the academy, foremen undergo leadership education, while drivers must pass a comprehensive road test to comply with Department of Transportation standards. Movers are also trained to wrap and protect furniture with heavy-duty blankets, corner protectors, and durable packing supplies—standards that are especially critical for long-distance relocations.

Technology plays a central role in ensuring a seamless customer experience. Foremen are trained to use tablets for electronic contracts and bills of lading, streamlining paperwork while improving accuracy. In addition, Experia provides clients with a real-time tracking system, allowing them to monitor their truck location, see when the crew is on the way, and stay updated throughout the move. This level of transparency has helped the company establish itself as one of the most innovative moving providers in the region.

“Moving should not feel stressful or uncertain—it should feel seamless,” said Nikola Radunovich, founder of Experia Moving. “Our mission is not just to move people’s belongings, but to deliver a hospitality-level service that creates raving fans and repeat customers. A successful move is about trust, communication, and care as much as it is about transportation.”

The company specializes in a wide range of services including residential moves, corporate relocations, and specialty moving for high-value items such as fine furniture, Peloton equipment, and delicate antiques. Every relocation, whether across town or cross-country, is handled with the same dedication to professionalism, safety, and customer satisfaction.

With its new presence in Greenwich, CT, Experia Moving is proud to extend its standard of excellence to Fairfield County residents and businesses. The company’s expansion marks an important milestone in its mission to redefine moving, combining rigorous training, advanced technology, and a customer-first philosophy

For more information about Experia Moving’s Greenwich, CT services, visit www.experiamoving.com or call 917-426-8177.

Media Contact
Company Name: Experia Moving
Contact Person: Nikola Radunovic
Email: Send Email
Phone: 9174268177
Address:233 W 111th St
City: New York
State: NY
Country: United States
Website: https://www.experiamoving.com/greenwich-ct-movers

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Experia Moving Expands Premium Moving Services to Greenwich, CT With Elite Team and VIP Experience

JAK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “JAK Inhibitor Pipeline Insight” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in JAK Inhibitor pipeline landscape. It covers the JAK Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the JAK Inhibitor therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive JAK Inhibitor pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive JAK Inhibitor Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ JAK Inhibitor Pipeline Outlook Report

Key Takeaways from the JAK Inhibitor Pipeline Report

  • On 19 August 2025, Geron Corporation announced a study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
  • On 14 August 2025, Pfizer announced a Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.
  • On 12 August 2025, Incyte Corporation conducted a study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
  • DelveInsight’s JAK Inhibitor pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for JAK Inhibitor treatment.
  • The leading JAK Inhibitor Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Arcutis Biotherapeutics/Reistone Biopharma and others.
  • Promising JAK Inhibitor Therapies such as Baricitinib, Busulfan, Cyclophosphamide, Ruxolitinib, Selinexor 60 mg, Ruxolitinib, Ritlecitinib, and others

Discover how the JAK Inhibitor treatment paradigm is evolving. Access DelveInsight’s in-depth JAK Inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ JAK Inhibitor Clinical Trials and Studies

JAK Inhibitor Emerging Drugs Profile

  • Povorcitinib: Incyte Corporation

Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo.

  • CPL409116: Celon Pharma

CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease.

  • ATI-2138: Aclaris Therapeutics

ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities.

  • SDC 1802: Sareum

SDC-1802 is an investigational Sareum’s TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer.

The JAK Inhibitor Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of JAK Inhibitor with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for JAK Inhibitor Treatment.
  • JAK Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • JAK Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the JAK Inhibitor market.

Get a detailed analysis of the latest innovations in the JAK Inhibitor pipeline. Explore DelveInsight’s expert-driven report today! @ JAK Inhibitor Unmet Needs

JAK Inhibitor Companies

Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Arcutis Biotherapeutics/Reistone Biopharma and others.

JAK Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

JAK Inhibitor Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming JAK Inhibitor Therapies and key JAK Inhibitor Developments @ JAK Inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the JAK Inhibitor Pipeline Report

  • Coverage- Global
  • JAK Inhibitor Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Arcutis Biotherapeutics/Reistone Biopharma and others.
  • Promising JAK Inhibitor Therapies – Baricitinib, Busulfan, Cyclophosphamide, Ruxolitinib, Selinexor 60 mg, Ruxolitinib, Ritlecitinib, and others
  • JAK Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • JAK Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in JAK Inhibitor drug development? Find out in DelveInsight’s exclusive JAK Inhibitor Pipeline Report—access it now! @ JAK Inhibitor Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Janus Kinase (JAK) Inhibitor: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Janus Kinase (JAK) Inhibitor– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Povorcitinib: Incyte Corporation
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CPL409116: Celon Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ATI-2138: Aclaris Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. SDC 1802: Sareum
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Janus Kinase (JAK) Inhibitor Key Companies
  21. Janus Kinase (JAK) Inhibitor Key Products
  22. Janus Kinase (JAK) Inhibitor- Unmet Needs
  23. Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers
  24. Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion
  25. Janus Kinase (JAK) Inhibitor Analyst Views
  26. Janus Kinase (JAK) Inhibitor Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitor-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: JAK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Respiratory Syncytial Virus Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the Respiratory Syncytial Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Respiratory Syncytial Virus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Respiratory Syncytial Virus Pipeline. Dive into DelveInsight’s comprehensive report today! @ Respiratory Syncytial Virus Pipeline Outlook

Key Takeaways from Respiratory Syncytial Virus Pipeline Report

  • On 19 August 2025, ModernaTX Inc. announced a study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days postinjection through 12 months.
  • On 17 August 2025, Shenzhen Shenxin Biotechnology Co., Ltd conducted a study will evaluate the safety, tolerability, and immunogenicity of 2 dose levels of IN006 in healthy participants who aged at 60 years or older; of a revaccination of IN006 given 12 months or 24 months after the initial vaccination.
  • On 14 August 2025, Pfizer conducted a phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
  • DelveInsight’s Respiratory Syncytial Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Respiratory Syncytial Virus treatment.
  • The leading Respiratory Syncytial Virus Companies such as AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
  • Promising Respiratory Syncytial Virus Pipeline Therapies such as JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.

Stay ahead with the most recent pipeline outlook for Respiratory Syncytial Virus. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Respiratory Syncytial Virus Treatment Drugs

Respiratory Syncytial Virus Emerging Drugs Profile

  • Clesrovimab: Merck Sharp & Dohme

Clesrovimab (MK-1654) is an investigational extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV-associated medically attended lower respiratory infection (MALRI). Clesrovimab is being studied in infants (pre-term and full-term) to provide rapid, durable protection through their first RSV season with a single, fixed-dose administration. Currently, the drug is in the Phase III stage of its development for the treatment of Respiratory Syncytial Virus (RSV). 

  • IVX A12: AstraZeneca

IVX-A12 is a potential bivalent first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses. The FDA has granted IVX-A12 Fast Track designation in adults ≥60 years of age. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate. Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and hMPV one month after vaccination and reconfirm previous immunogenicity data seen in the Phase I trial. The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

  • MV-012-968: Meissa Vaccines, Inc

MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants from RSV. MV-012-968 is well-tolerated, highly attenuated, and induces a strong systemic and mucosal IgA antibody response in RSV-naïve children. Meissa is currently enrolling participants between the ages of six and 36 months in a Phase Ic clinical study at multiple sites in the U.S. to evaluate the safety and immunogenicity of MV-012-968. MV-012-968 was generated using the company’s proprietary AttenuBlockTM synthetic biology platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

The Respiratory Syncytial Virus Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
  • Respiratory Syncytial Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market

Explore groundbreaking therapies and clinical trials in the Respiratory Syncytial Virus Pipeline. Access DelveInsight’s detailed report now! @ New Respiratory Syncytial Virus Drugs

Respiratory Syncytial Virus Companies

AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.

Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Respiratory Syncytial Virus Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Unveil the future of Respiratory Syncytial Virus Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Respiratory Syncytial Virus Market Drivers and Barriers

Scope of the Respiratory Syncytial Virus Pipeline Report

  • Coverage- Global
  • Respiratory Syncytial Virus Companies- AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
  • Respiratory Syncytial Virus Pipeline Therapies- JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
  • Respiratory Syncytial Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Respiratory Syncytial Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Respiratory Syncytial Virus Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Respiratory Syncytial Virus Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Respiratory Syncytial Virus (RSV): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Respiratory Syncytial Virus (RSV) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Respiratory Syncytial Virus (RSV) Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Clesrovimab: Merck Sharp & Dohme
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. IVX A12: AstraZeneca
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. MV-012-968: Meissa Vaccines, Inc
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug Name: Company Name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Respiratory Syncytial Virus (RSV) Key Companies
  23. Respiratory Syncytial Virus (RSV) Key Products
  24. Respiratory Syncytial Virus (RSV)- Unmet Needs
  25. Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
  26. Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
  27. Respiratory Syncytial Virus (RSV) Analyst Views
  28. Respiratory Syncytial Virus (RSV) Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Respiratory Syncytial Virus Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Heart Failure Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Heart Failure Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape. It covers the Heart Failure pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Heart Failure pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Heart Failure Treatment Landscape @ Heart Failure Pipeline Outlook

Key Takeaways from the Heart Failure Pipeline Report

  • On 15 August 2025, Bristol-Myers Squibb announced a study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
  • On 14 August 2025, Pfizer conducted a study will take either the study medicine (PF-07328948) tablets, or placebo tablets, once daily, by mouth, every day for 36 weeks. The study determines if the study medicine (PF-07328948) is safe and effective compared to placebo in people with heart failure who are already taking standard-of-care medications for heart failure that include sodium-glucose cotransporter 2 (SGLT2) inhibitors. Participants will be involved in this study for about 48 weeks. During this time, participants will visit the study clinic 15 times. In general, 5 of these visits may be performed at home by phone and the other 10 visits will take place at the study site.
  • On 12 August 2025, Novo Nordisk A/S organized a study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
  • DelveInsight’s Heart Failure pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Heart Failure treatment.
  • The Heart Failure Companies such as Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics and others.
  • Promising Heart Failure Pipeline Therapies such as Pirfenidone, KW-3902IV, Relaxin, Tolvaptan, Furosemide, Torsemide, Bumetanide, GSK716155, Dapagliflozin and others.

Stay informed about the cutting-edge advancements in Heart Failure treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Heart Failure Clinical Trials Assessment

Heart Failure Emerging Drugs Profile

  • Rexlemestrocel-L: Mesoblast

Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Enrollment of 566 patients has been completed in a placebo-controlled Phase III trial to evaluate a single dose of Revascor in Class II/III CHF patients across multiple sites in North America. Patients with advanced heart failure constitute the majority of the patients enrolled in this clinical trial program. Currently, the drug is in Phase III stage of its development for the treatment of heart failure.

  • HU 6: Rivus Pharmaceuticals

HU6 is a controlled metabolic accelerator (CMA) that provides a novel, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat throughout the body. Currently, the drug is in Phase II stage of its development for the treatment of heart failure.

  • HS-001: Heartseed Inc

HS-001, is allogeneic iPSC-derived, highly purified ventricular cardio myocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for the administration of the spheroids into the myocardial layer of the heart. The expected mechanism of action is that the transplanted cardio myocytes electrically couple with the patient’s myocardium to improve cardiac output by remuscularisation, and secretion of angiogenic factors to form new blood vessels around the transplant site (neovascularization). In June 2021, Heartseed and Novo Nordisk entered into global collaboration and license agreement for stem cell-based therapy for heart failure. Currently, the drug is in Phase I/II stage of its development for the treatment of heart failure.

  • Ribonucleotide reductase based gene therapy: StemCardia

Ribonucleotide reductase based gene therapy is a novel investigational product candidate being developed by StemCardia. The drug candidate is based on Gene transference and Ribonucleotide reductase modulators mechanism of action. Currently, the drug is in preclinical stage of its development for the treatment of heart failure.

The Heart Failure Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
  • Heart Failure Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.

Learn more about Heart Failure Drugs opportunities in our groundbreaking Heart Failure research and development projects @ Heart Failure Unmet Needs

Heart Failure Companies

Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics and others.

Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Heart Failure Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Stay informed about how we’re transforming the future of Cardiovascular Diseases @ Heart Failure Market Drivers and Barriers, and Future Perspectives

Scope of the Heart Failure Pipeline Report

  • Coverage- Global
  • Heart Failure Companies- Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics and others.
  • Heart Failure Pipeline Therapies- Pirfenidone, KW-3902IV, Relaxin, Tolvaptan, Furosemide, Torsemide, Bumetanide, GSK716155, Dapagliflozin and others.
  • Heart Failure Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Heart Failure Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Heart Failure Pipeline on our website @ Heart Failure Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Heart Failure: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Heart Failure – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Rexlemestrocel-L: Mesoblast
  9. Mid Stage Products (Phase II)
  10. HU 6: Rivus Pharmaceuticals
  11. Early Stage Products (Phase I/II)
  12. HS-001: Heartseed Inc
  13. Preclinical and Discovery Stage Products
  14. Ribonucleotide reductase based gene therapy: StemCardia
  15. Inactive Products
  16. Heart Failure Key Companies
  17. Heart Failure Key Products
  18. Heart Failure – Unmet Needs
  19. Heart Failure – Market Drivers and Barriers
  20. Heart Failure – Future Perspectives and Conclusion
  21. Heart Failure Analyst Views
  22. Heart Failure Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/heart-failure-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Heart Failure Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Cataract Surgery Devices Market to Grow at a CAGR of ~5.50% by 2032, Driven by Aging Populations and Technological Advancements | DelveInsight

“Cataract Surgery Devices Market”
The cataract surgery devices market is steadily growing due to the rising prevalence of cataracts, the leading cause of global blindness, and increased use of advanced surgical techniques. According to WHO, cataracts cause nearly 51% of blindness worldwide, mainly affecting aging populations. Longer life expectancy and improved healthcare in emerging markets are driving demand for effective and affordable cataract surgery solutions.

Technological innovations such as femtosecond laser-assisted cataract surgery (FLACS), premium intraocular lenses (IOLs), and micro-incision surgical systems are transforming the standard of care by offering greater precision, reduced recovery times, and improved patient outcomes. Additionally, the growing focus on outpatient surgical centers and ambulatory care is expanding access to cataract procedures, further driving device adoption.

The integration of digital technologies, including AI-powered diagnostic tools and image-guided surgery systems, is also reshaping the market by enhancing surgical accuracy and streamlining workflows. Leading manufacturers are investing heavily in next-generation IOLs, such as extended depth-of-focus and multifocal lenses, to address unmet needs in vision restoration.

As a result, the cataract surgery devices market is projected to sustain strong growth through 2032, supported by favorable demographics, healthcare spending, and continuous R&D investments.

DelveInsight’s Cataract Surgery Devices Market Insights report delivers a comprehensive analysis of current and forecasted market dynamics, growth drivers, challenges, regulatory landscape, and competitive strategies, along with detailed profiles of key players driving the evolution of the cataract surgery devices industry.

 

Key Takeaways from the Cataract Surgery Devices Market Report

• The cataract surgery devices market was valued at USD 7.73 billion in 2023 and is expected to grow at a CAGR of 5.50%, reaching USD 10.66 billion by 2032.

• As per DelveInsight estimates, North America is anticipated to dominate the global Cataract Surgery Devices market during the forecast period.

• Notable cataract surgery device companies such as Alcon Inc., Johnson & Johnson Services, Inc., NIDEK CO., LTD., ZEISS Group, Bausch Health Companies Inc., Ziemer Ophthalmic Systems AG, Abbott Laboratories, HOYA Corporation, Aurolab, Hanita Lenses Ltd, Topcon Corporation, STAAR SURGICAL, Bohus BioTech AB, Eyekon Medical, CIMA Technology Inc., Medisonic Equipments Pvt. Ltd., Opthalmika Ltd, Lumenis Be Ltd., Essilor International, Oertli Instrumente AG, and several others are currently operating in the cataract surgery devices market.

• In May 2025, Atia Vision, a Shifamed portfolio company, received FDA IDE approval to begin a feasibility study of its OmniVu™ Lens System—an innovative intraocular lens aimed at restoring dynamic vision after cataract surgery, surpassing current presbyopia-correcting lenses.

• In July 2024, Oertli Instrumente AG announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Faros anterior cataract surgery system. It is a high-performance surgical platform designed for cataract, vitreoretinal, and glaucoma procedures. Its advanced fluid and vacuum control capabilities provide advanced precision, allowing it to adapt seamlessly to varying cataract hardness levels.

• In June 2024, Alcon received U.S. Food and Drug Administration (FDA) 510(k) clearance for UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS). This system is developed to offer enhanced precision for vitreoretinal procedures in cataract surgery.

To read more about the latest highlights related to the cataract surgery devices market, get a snapshot of the key highlights entailed in the Global Cataract Surgery Devices Market Report

 

Cataract Surgery Devices Overview

Cataract surgery devices are used to remove the eye’s cloudy natural lens and replace it with an artificial intraocular lens (IOL). Key devices include phacoemulsification systems, femtosecond lasers, intraocular lenses, ophthalmic viscoelastic devices (OVDs), and surgical instruments. These tools enable precise, minimally invasive procedures with improved visual outcomes. Technological advancements, such as premium IOLs and image-guided systems, are enhancing surgical accuracy and patient satisfaction.

 

Cataract Surgery Devices Market Insights

North America is projected to lead the cataract surgery devices market in 2023, driven by a growing aging population, rising prevalence of cataracts, and increasing risk factors such as diabetes, hypertension, and obesity. According to CDC data (May 2024), over 20.5 million Americans aged 40 and above had cataracts in 2022, a number expected to rise, while Canada reported one in three individuals classified as obese, a known cataract risk factor. This rising burden is fueling demand for advanced surgical solutions. Companies like Johnson & Johnson MedTech and Alcon Canada are actively expanding treatment options with FDA-approved and newly launched intraocular lenses, supporting the region’s strong market growth through technological innovation and increasing patient needs.

To know more about why North America is leading the market growth in the cataract surgery devices market, get a snapshot of the Cataract Surgery Devices Market Outlook

 

Cataract Surgery Devices Market Dynamics

The cataract surgery devices market is experiencing significant growth driven by the rising global prevalence of cataracts and vision impairment. According to WHO (2023), over 2.2 billion people worldwide suffer from near or distance vision loss, with over 516,000 cataract surgeries performed in England alone in 2023. Aging remains the leading risk factor, as more than 50% of individuals aged 80+ in the U.S. had cataracts or underwent surgery, according to NIH data. With the global population aged 60+ expected to double by 2050, the demand for cataract procedures and surgical devices is set to increase. Additionally, lifestyle-related conditions like diabetes, which affected 537 million adults in 2021 and is projected to reach 783 million by 2045 (IDF, 2023), further contribute to cataract development. In response, companies like Alcon are innovating devices like the AcrySof® IQ Vivity™ IOL to improve visual outcomes. However, challenges such as surgical complications and limited device access in developing regions may slightly restrain market growth.

Get a sneak peek at the cataract surgery devices market dynamics @ https://www.delveinsight.com/report-store/cataract-surgery-devices-market

 

Coverage: Global

Study Period: 2022 to 2032

Cataract Surgery Devices Market CAGR: ~5.50%

Key Cataract Surgery Devices Companies: Alcon Inc., Johnson & Johnson Services, Inc., NIDEK CO., LTD., ZEISS Group, Bausch Health Companies Inc., Ziemer Ophthalmic Systems AG, Abbott Laboratories, HOYA Corporation, Aurolab, Hanita Lenses Ltd, Topcon Corporation, STAAR SURGICAL, Bohus BioTech AB, Eyekon Medical, CIMA Technology Inc., Medisonic Equipments Pvt. Ltd., Ophthalmika Ltd, Lumenis Be Ltd., Essilor International, Oertli Instrumente AG, and others.

 

Cataract Surgery Devices Market Segmentation

Market Segmentation By Product Type: Phacoemulsification Systems, Femtosecond Lasers, Intraocular Lenses, Ophthalmic Viscosurgical Devices, and others.

Market Segmentation By End User: Hospitals and Specialty Clinics.

Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World.

Which MedTech key players in the cataract surgery devices market are set to emerge as the trendsetter, explore @ Cataract Surgery Devices Companies

 

Table of Contents

1. Electrophysiology Devices Market Report Introduction

2. Electrophysiology Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Electrophysiology Devices Market Key Factors Analysis

6. Electrophysiology Devices Market Porter’s Five Forces Analysis

7. Electrophysiology Devices Market Layout

8. Electrophysiology Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

 

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cataract Surgery Devices Market to Grow at a CAGR of ~5.50% by 2032, Driven by Aging Populations and Technological Advancements | DelveInsight

Diabetic Nephropathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Diabetic Nephropathy Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Nephropathy pipeline landscape. It covers the Diabetic Nephropathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Nephropathy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diabetic Nephropathy pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Nephropathy Treatment Landscape @ Diabetic Nephropathy Pipeline Outlook

Key Takeaways from the Diabetic Nephropathy Pipeline Report

  • On 11 August 2025, Novartis Pharmaceuticals announced a AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
  • On 11 August 2025, Inversago Pharma Inc. conducted a study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.
  • DelveInsight’s Diabetic Nephropathy pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Diabetic Nephropathy treatment.
  • The leading Diabetic Nephropathy Companies such as Serodus AS, Curacle, Certa Therapeutics, Cosette Pharmaceuticals, Boehringer Ingelheim, Lewis and Clark Pharmaceuticals, Shanghai Alebund Pharmaceuticals, Celros Biotech, Inversago Pharma Inc., Akebia Therapeutics, Palatin Technologies, Inc, and Chinook Therapeutics and others.
  • Promising Diabetic Nephropathy Pipeline Therapies such as BI 685509, BAY94-8862, Telmisartan capsule 40 mg, Finerenone (BAY94-8862), Canagliflozin, Nidufexor, MT-3995, Nidufexor, Repository Corticotropin Injectio, Bindarit and others.

Stay informed about the cutting-edge advancements in Diabetic Nephropathy treatments. Download for updates and be a part of the revolution in Endocrinology and Metabolic Disorders Care @ I Diabetic Nephropathy Clinical Trials Assessment

Diabetic Nephropathy Emerging Drugs Profile

  • SER150: Serodus AS

SER150 is an anti-inflammatory compound with a novel mode of action both inhibiting thromboxane synthase as well as blocking the thromboxane (TP) receptor. SER150 is expected to specifically inhibit the inflammatory processes in various segments of the diabetic kidney and reduce the progression of renal impairment whereby the amount of protein excreted in urine will decrease. Treatment with ACE-inhibitor antihypertensives is the golden standard of treatment of diabetic nephropathy but that treatment does not inhibit the fundamental causes of renal damage nor does it cure the disease. Newer antidiabetic drugs have demonstrated a decrease in loss of kidney function over time. Since the inflammation is a progressive process causing loss of the renal function, SER150 could potentially become a very significant combination (add-on) therapy as standard daily treatment in patients with diabetic kidney disease. It is expected that SER150 treatment delays progression or even prevents development of the disease. Consequently, SER150 may have a blockbuster market potential. Currently, the drug is in Phase II/III stage of its development for the treatment of diabetic kidney disease

  • CU01: Curacle

CU01 Dimethyl fumarate (DMF) which is being developed by Curacle. CU01 inhibits TGF-β/SMAD signaling by activating Nrf2 and has an excellent therapeutic effect in reducing renal fibrosis by suppressing the expression of extracellular matrix. In the previous clinical studies CU01 showed a significant improvement in the amount of change in eGFR from week 6 after administration, and the consistently increasing change in GFR continued until week 12. CU01 group suppressed the progression of diabetic nephropathy by gradually increasing eGFR during the administration period, so it is presumed to have an improvement effect on diabetic nephropathy. In the CU01 group, the ACR value at week 12 compared to the baseline was statistically significantly decreased (p=0.0441). Currently, the drug is in Phase II stage of its development for the treatment of diabetic nephropathy.

  • CTA 382: Certa Therapeutics

CTA 382 is a novel small molecule therapy developed by Certa Therapeutics targeting chronic inflammatory and fibrotic diseases. It selectively inhibits the activity of key pro-inflammatory pathways involved in fibrosis and tissue damage. The drug is being investigated for conditions such as idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD) to improve clinical outcomes by reducing fibrosis and inflammation. Currently, the drug is in Preclinical stage of its development for the treatment of diabetic nephropathy.

The Diabetic Nephropathy Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Nephropathy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Nephropathy Treatment.
  • Diabetic Nephropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Diabetic Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Nephropathy market.

Learn more about Diabetic Nephropathy Drugs opportunities in our groundbreaking Diabetic Nephropathy research and development projects @ Diabetic Nephropathy Unmet Needs

Diabetic Nephropathy Companies

Serodus AS, Curacle, Certa Therapeutics, Cosette Pharmaceuticals, Boehringer Ingelheim, Lewis and Clark Pharmaceuticals, Shanghai Alebund Pharmaceuticals, Celros Biotech, Inversago Pharma Inc., Akebia Therapeutics, Palatin Technologies, Inc, and Chinook Therapeutics and others.

Diabetic Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Diabetic Nephropathy Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Diabetic Nephropathy Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Stay informed about how we’re transforming the future of Endocrinology and Metabolic Disorders @ Diabetic Nephropathy Market Drivers and Barriers, and Future Perspectives

Scope of the Diabetic Nephropathy Pipeline Report

  • Coverage- Global
  • Diabetic Nephropathy Companies- Serodus AS, Curacle, Certa Therapeutics, Cosette Pharmaceuticals, Boehringer Ingelheim, Lewis and Clark Pharmaceuticals, Shanghai Alebund Pharmaceuticals, Celros Biotech, Inversago Pharma Inc., Akebia Therapeutics, Palatin Technologies, Inc, and Chinook Therapeutics and others.
  • Diabetic Nephropathy Pipeline Therapies- BI 685509, BAY94-8862, Telmisartan capsule 40 mg, Finerenone (BAY94-8862), Canagliflozin, Nidufexor, MT-3995, Nidufexor, Repository Corticotropin Injectio, Bindarit and others.
  • Diabetic Nephropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diabetic Nephropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Diabetic Nephropathy Pipeline on our website @ Diabetic Nephropathy Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Diabetic Nephropathy Overview
  4. Diabetic Nephropathy Pipeline Therapeutics
  5. Diabetic Nephropathy Therapeutic Assessment
  6. Diabetic Nephropathy– DelveInsight’s Analytical Perspective
  7. Late Stage Diabetic Nephropathy Products (Phase III)
  8. Drug Name: Company Name
  9. Mid Stage Diabetic Nephropathy Products (Phase II/III)
  10. SER150: Serodus AS
  11. Early Stage Diabetic Nephropathy Products (Phase I)
  12. Drug Name: Company Name
  13. Preclinical and Discovery Stage PDiabetic Nephropathy roducts
  14. CTA 382: Certa Therapeutics
  15. Inactive Products
  16. Diabetic Nephropathy Companies
  17. Diabetic Nephropathy Products
  18. Diabetic Nephropathy Unmet Needs
  19. Diabetic Nephropathy Market Drivers and Barriers
  20. Diabetic Nephropathy Future Perspectives and Conclusion
  21. Diabetic Nephropathy Analyst Views
  22. 22. Appendixytt9

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-nephropathy-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Nephropathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Orthopedic Trauma Devices Market Poised to Register a CAGR of ~6.43% by 2032 | DelveInsight

“Orthopedic Trauma Devices Market”
The orthopedic trauma devices market is experiencing robust growth, driven by the rising incidence of road traffic accidents, sports-related injuries, and age-related orthopedic conditions such as osteoporosis and fractures. With the global population aging rapidly and urbanization contributing to higher accident rates, the demand for advanced trauma fixation products, including plates, screws, intramedullary nails, and external fixators, is expanding significantly.

Technological advancements, such as bioabsorbable implants, 3D-printed devices, and minimally invasive surgical techniques, are reshaping treatment outcomes, offering patients faster recovery and improved mobility. Furthermore, the integration of smart implants with sensors and real-time monitoring capabilities is emerging as a transformative trend, enhancing post-surgical care and rehabilitation.

As healthcare systems worldwide emphasize value-based care and efficient fracture management, adoption of innovative orthopedic trauma solutions is expected to accelerate. Consequently, the market is projected to maintain steady growth momentum through 2032, supported by investments in R&D and the increasing availability of trauma care facilities across both developed and emerging economies.

DelveInsight’s Orthopedic Trauma Devices Market Insights report provides a detailed evaluation of current and forecast market dynamics, key growth drivers, barriers, regulatory landscape, competitive positioning, and in-depth profiles of leading companies shaping the future of the orthopedic trauma devices market.

 

Key Takeaways from the Orthopedic Trauma Devices Market Report

• The orthopedic trauma devices market was valued at USD 7.01 billion in 2023 and is projected to reach USD 10.15 billion by 2032, growing at a CAGR of 6.43% from 2025 to 2032.

• As per DelveInsight estimates, North America is anticipated to dominate the global Orthopedic Trauma Devices market during the forecast period.

• Notable Orthopedic Trauma Devices companies such as Zimmer Biomet, Orthofix Medical Inc., Johnson & Johnson Services, Inc., B. Braun Meslungen AG, Stryker, Medtronic, Acumed, INION OY, Orthomed, Smith & Nephew Plc, CONMED Corporation, Bioretec Ltd., Arthrex Inc., JEIL MEDICAL CORPORATION, OsteoMed, Medartis AG, Biorez, Invibio Ltd., Advanced Orthopaedic Solutions, DJO, LLC, and several others are currently operating in the Orthopedic Trauma Devices market.

• In May 2025, Massachusetts-based Trax Surgical, LLC received FDA 510(k) clearance for its LINKT™ Compression Staple System, designed for fracture repair, joint fusion, and osteotomy procedures in orthopedic extremities.

• In April 2025, Ventris Medical announced U.S. FDA 510(k) clearance for Backpack® (Porous Biologic Scaffold) for intervertebral disc use. Designed to promote cell growth and bone formation, Backpack® supports orthopedic and spinal fusion surgeries and is available with either osteoinductive Allocell® AF fibers or surface-activated Amplify® granules.

• In February 2025, Atreon Orthopedics, LLC, a Columbus-based innovator in tissue healing, announced FDA 510(k) clearance and the full market launch of BioCharge® Autobiologic Matrix. This bioresorbable synthetic implant is designed to improve rotator cuff repair integrity and long-term patient outcomes.

• In October 2024, Globus Medical, Inc., a leading musculoskeletal solutions company, announced the continued growth and expansion of its orthopedic trauma product portfolio. Globus introduced several new system extensions in 2024 and received 510(k) clearance from the U.S. Food and Drug Administration for its first suture-based product, the TENSOR™ Suture Button System. Among the newly launched next-generation systems were the ANTHEM™ II Distal Radius Volar Plates, AUTOBAHN™ Trochanteric Nail PRO Instruments, and CAPTIVATE™ SOLA Headless Screws.

To read more about the latest highlights related to the Orthopedic Trauma Devices market, get a snapshot of the key highlights entailed in the Global Orthopedic Trauma Devices Market Report

 

Orthopedic Trauma Devices Overview

Orthopedic trauma devices are medical implants and tools designed to treat injuries to the bones and soft tissues, such as fractures, dislocations, and ligament tears. These devices—including screws, plates, rods, pins, and external fixators—are used to stabilize and support the affected area, ensuring proper alignment and faster healing. They play a critical role in trauma care, particularly following accidents, falls, or sports injuries. With the growing global incidence of orthopedic injuries, aging populations, and a shift toward minimally invasive surgical techniques, the orthopedic trauma devices market is witnessing steady growth, driven by continuous innovation and improved surgical outcomes.

 

Orthopedic Trauma Devices Market Insights

North America is expected to dominate the orthopedic trauma devices market from 2023 through 2032, driven by a high incidence of hip fractures, avascular necrosis, and shoulder injuries, along with a strong healthcare infrastructure and presence of major players like Johnson & Johnson, Stryker, and Zimmer Biomet. According to the American Academy of Orthopaedic Surgeons (2024), over 300,000 hip fractures occur annually in the U.S., primarily in individuals aged 65 and older. The NIH (2023) reports 20,000–30,000 new avascular necrosis cases each year, while data from the American Academy of Physical Medicine and Rehabilitation (2022) highlights a high burden of shoulder dislocations, proximal humerus fractures, and clavicle injuries. Orthopedic trauma devices such as internal fixators, prosthetics, plates, and external supports play a critical role in managing these injuries, aiding in pain relief, bone stabilization, and functional recovery. With advanced medical services and strong distribution networks ensuring accessibility, the region remains a key driver of market growth through the forecast period.

To know more about why North America is leading the market growth in the Orthopedic Trauma Devices market, get a snapshot of the Orthopedic Trauma Devices Market Outlook

 

Orthopedic Trauma Devices Market Dynamics

According to the World Health Organization (2023), around 344 million people globally are affected by osteoarthritis, with 73% over the age of 55 and 60% being female. Additionally, 13 million individuals are living with rheumatoid arthritis. These degenerative joint conditions contribute significantly to the demand for orthopedic trauma devices, which help manage joint damage, inflammation, and loss of mobility. Sports and recreational injuries also drive this demand, data from the National Safety Council (2024) reported 3.7 million emergency room visits in 2023 for such injuries, with a notable 8% rise in exercise-related injuries. Furthermore, the global burden of hip fractures is rising, especially in Asia, where over 50% of osteoporotic hip fractures are projected to occur by 2050.

These growing orthopedic needs have underscored the importance of trauma devices in joint stabilization, mobility restoration, and fracture recovery. However, despite their benefits, risks such as nerve or blood vessel injury, stiffness, and complications from device placement may limit their use, posing challenges to market expansion.

Get a sneak peek at the Orthopedic Trauma Devices market dynamics @ https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market

 

Coverage: Global

Study Period: 2022 to 2032

Orthopedic Trauma Devices Market CAGR: ~6.43%

Key Orthopedic Trauma Devices Companies: Zimmer Biomet, Orthofix Medical Inc., Johnson & Johnson Services, Inc., B. Braun Meslungen AG, Stryker, Medtronic, Acumed, INION OY, Orthomed, Smith & Nephew Plc, CONMED Corporation, Bioretec Ltd., Arthrex Inc., JEIL MEDICAL CORPORATION, OsteoMed, Medartis AG, Biorez, Invibio Ltd., Advanced Orthopaedic Solutions, DJO, LLC, and others.

 

Orthopedic Trauma Devices Market Segmentation

Market Segmentation By Product Type: Internal Fixators [Plates & Screws, Rods & Pins, and Others] and External Fixators [Unilateral, Circular, Hybrid, and others].

Market Segmentation By Absorbability: Non-Absorbable and Resorbable

Market Segmentation By End User: Hospitals, Ambulatory Surgical Centers, and others.

Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World.

Which MedTech key players in the Orthopedic Trauma Devices market are set to emerge as the trendsetter, explore @ Orthopedic Trauma Devices Companies

 

Table of Contents

1. Electrophysiology Devices Market Report Introduction

2. Electrophysiology Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Electrophysiology Devices Market Key Factors Analysis

6. Electrophysiology Devices Market Porter’s Five Forces Analysis

7. Electrophysiology Devices Market Layout

8. Electrophysiology Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

 

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Orthopedic Trauma Devices Market Poised to Register a CAGR of ~6.43% by 2032 | DelveInsight

U.S. Data Center Colocation Market Investment to Reach USD 57.32 Billion by 2030 with 14.88% CAGR | Arizton

“U.S. Data Center Colocation Market Research Report by Arizton”
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025–2030.

According to Arizton latest research report, U.S. data center colocation market is growing at a CAGR of 14.88% during 2024-2030.

 

Looking for More Information? Click: https://www.arizton.com/market-reports/us-data-center-colocation-market

 

Report Scope:

Market Size – Investment (2030): USD 57.32 Billion

Market Size – Investment (2024): USD 24.94 Billion

CAGR – Investment (2024-2030):14.88%

Market Size – Area (2030):18.20 Million Square Feet

Market Size – Power Capacity (2030):4,520 Mw

Market Size – Colocation Revenue (2030): USD 47.50 Billion

Historic Year:2021-2023

Base Year:2024

Forecast Year:2025-2030

Market Segmentation: Colocation Type, Infrastructure, Electrical Infrastructure, Mechanical Infrastructure, Cooling Systems, Cooling Techniques, General Construction, Tier Standard, And Geography

Largest Region by Investment: South-Eastern U.S.

Fastest Growing Region by Investment: North-Eastern U.S.

Geographical Analysis: South-Eastern U.S., South-Western U.S., Western U.S., Mid-Western U.S., And North-Eastern U.S.

 

U.S. Data Centers: World’s Established Colocation Market worldwide

The U.S. data center colocation market is witnessing strong growth, driven by surging demand for AI, cloud computing, and digital services across industries. As public and private sectors accelerate digital transformation, the need for high-performance computing, low-latency operations, and secure data storage is intensifying.

Leading operators, including Aligned Data Centers, Digital Realty, Equinix, CyrusOne, and STACK Infrastructure, are investing billions nationwide. The Southeastern U.S., led by Virginia, Georgia, and North Carolina, dominates with over 50% of installed power capacity, while the Northeastern U.S. is emerging as a key growth region. Notable expansions include Aligned’s Maryland Quantum Frederick Park campus, set to add 72 MW of capacity.

Construction costs remain high, with Silicon Valley reporting the highest at $12.80 per watt in 2024, a 5.35% increase from 2023, reflecting ongoing land, labor, and infrastructure challenges. Despite these challenges, strong demand and continued investment are set to drive robust growth and innovation across the U.S. colocation market.

 

Tracking U.S. Data Center Growth: Top Players’ Strategic Moves in 2025

  • TierPoint Expansion: In April 2025, U.S.-based data center company TierPoint secured $500 million through an asset-backed securities issuance to fuel ongoing growth and expansion.
  • Macquarie Investment: In January 2025, investment firm Macquarie announced plans to invest up to $5 billion in Applied Digital’s AI data center operations, starting with a $900 million injection into the Ellendale campus in North Dakota.

 

U.S. Data Centers Revolutionize Cooling with Smart Tech

U.S. data centers are embracing innovative power and cooling solutions to keep pace with the rapid growth of high-density AI and cloud workloads. As rack densities climb beyond 20–30 kW, traditional air-cooling falls short, prompting operators to adopt liquid cooling, modular power architectures, and energy reuse systems that balance performance, cost efficiency, and sustainability.

Leading the way, Compass Data centers is investing in HVO-fueled generators, which enhance reliability, extend fuel life, and cut greenhouse gas emissions without altering existing infrastructure. Meanwhile, Prometheus Hyperscale is rolling out long-duration energy storage (LDES) across its portfolio, offering over 20 years of sustainable, rare-earth-free power. These advancements are reshaping the U.S. data center colocation market, enabling smarter, more energy-efficient, and AI-ready infrastructure for the digital era.

 

How AI Workloads Are Empowering U.S. Data Centers

AI adoption is accelerating across the U.S., driving a surge in demand for AI-ready data centers and advanced digital infrastructure. In January 2025, the government launched the Stargate AI infrastructure initiative in collaboration with private partners, including OpenAI, to strengthen the country’s AI capabilities. Leading operators are responding by developing purpose-built, sustainable data centers, such as Edged’s facility in Mesa, Arizona, designed for highly efficient AI model training and inference.

As organizations increasingly rely on large volumes of high-quality, structured data to power automation and machine learning, the need for advanced, scalable, and energy-efficient infrastructure is reshaping the U.S. data center colocation market and creating new opportunities for innovation and investment.

 

Book the Free Sample @: https://www.arizton.com/market-reports/us-data-center-colocation-market

 

Prominent Data Center Investors

  1. Aligned Data Centers
  2. Compass Datacenters
  3. CyrusOne
  4. DataBank
  5. Digital Realty
  6. Equinix
  7. NTT DATA
  8. QTS Realty Trust
  9. STACK Infrastructure
  10. Vantage Data Centers

Other Data Center Investors

  1. Applied Digital
  2. American Tower
  3. AUBix
  4. Centersquare
  5. CloudHQ
  6. Cologix
  7. COPT Data Center Solutions
  8. Core Scientific
  9. Corscale Data Centers
  10. DartPoints
  11. DC BLOX
  12. DigiPowerX
  13. EdgeConneX
  14. EdgeCore Digital Infrastructure
  15. Element Critical
  16. Flexential
  17. Fifteenfortyseven Critical Systems Realty (1547)
  18. H5 Data Centers
  19. HostDime
  20. HUT 8
  21. Iron Mountain
  22. Netrality Data Centers
  23. Novva Data Centers
  24. PheonixNAP
  25. PowerHouse Data Centers
  26. Prime Data Centers
  27. Sabey Data Centers
  28. Skybox Datacenters
  29. Stream Data Centers
  30. Switch
  31. T5 Data Centers
  32. TierPoint
  33. Yondr
  34. 365 Data Centers
  35. 5C Data Centers

New Entrants

  1. Ardent Data Centers
  2. CloudBurst Data Center
  3. Colovore
  4. Crane Data Centers
  5. Edged
  6. NE Edge
  7. Prometheus Hyperscale
  8. Quantum Loophole
  9. Rowan Digital Infrastructure
  10. Tract

Market Segmentation & Forecast

Colocation Type

  1. Retail Colocation
  2. Wholesale Colocation

Infrastructure

  1. Electrical Infrastructure
  2. Mechanical Infrastructure
  3. General Construction

Electrical Infrastructure

  1. UPS Systems
  2. Generators
  3. Transfer Switches & Switchgear
  4. PDUs
  5. Other Electrical Infrastructure

Mechanical Infrastructure

  1. Cooling Systems
  2. Racks
  3. Other Mechanical Infrastructure

Cooling Systems

  1. CRAC & CRAH Units
  2. Chiller Units
  3. Cooling Towers, Condensers & Dry Coolers
  4. Other Cooling Units

Cooling Techniques

  1. Air-based Cooling
  2. Liquid-based Cooling

General Construction

  1. Core & Shell Development
  2. Installation & Commissioning Services
  3. Engineering & Building Design
  4. Fire Detection & Suppression
  5. Physical Security
  6. DCIM

Tier Standard

  1. Tier I & II
  2. Tier III
  3. Tier IV

Geography

  1. Southeastern US
  2. Southwestern US
  3. Western US
  4. Midwestern US
  5. Northeastern US

 

Other Related Reports that Might be of Your Business Requirement   

U.S. Data Center Market Landscape 2025-2030

https://www.arizton.com/market-reports/us-data-center-market-analysis

U.S. Data Center Construction Market – Industry Outlook & Forecast 2025-2030

https://www.arizton.com/market-reports/united-states-data-center-construction-market-2024

 

What Key Findings Will Our Research Analysis Reveal?   

  1. How big is the U.S. data center colocation market?
  2. What is the estimated market size in terms of area in the U.S. data center colocation market by 2030?
  3. What is the growth rate of the U.S. data center colocation market?
  4. How many MW of power capacity is expected to reach the U.S. data center colocation market by 2030?
  5. What are the key trends in the U.S. data center colocation market?

 

Why Arizton?                                              

100% Customer Satisfaction                                              

24×7 availability – we are always there when you need us                                              

200+ Fortune 500 Companies trust Arizton’s report                                              

80% of our reports are exclusive and first in the industry                                              

100% more data and analysis                                              

1500+ reports published till date                            

                 

Post-Purchase Benefit                                          

  1. 1hr of free analyst discussion                                          
  2. 10% off on customization                       

                

About Us:                                                                                   

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/us-data-center-colocation-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: U.S. Data Center Colocation Market Investment to Reach USD 57.32 Billion by 2030 with 14.88% CAGR | Arizton

Rising Trend of Self-Reliant Renovations Fuels Global DIY Home Improvement Market Growth- Profshare Market Research

“DIY Home Improvement Market Analysis and Forecast 2032”
DIY Home Improvement Market is anticipated to reach USD 1173990 million by 2032 with a Compound Annual Growth Rate (CAGR) of 4.5 % from 2026 to 2032. Primary market drivers include Rising Renovation Demand, Growing Homeownership, Technological advancement and Digitalization.

The latest premium report by Profshare Market Research, “DIY Home Improvement Market by Product Type (Building Materials, Paints and Wallpaper, Decor and Indoor Garden, Plumbing Materials and Equipment, Tools & Hardware, Lighting Products and Others) by Distribution Channel (Online, Offline) and Forecast 2026-2032”

 

DIY Home Improvement Market Segmentation:

By Product types, the Paints and Wallpaper segment is projected to show the highest CAGR during the forecast period.

Building Materials, Paints and Wallpaper, Decor and Indoor Garden, Plumbing Materials and Equipment, Tools & Hardware, and Lighting Products are the main Product types analysed in the research report. Paints and Wallpaper hold the maximum market share and continue to grow at a significant rate during the forecast period. Low cost, minimal skill and quick results are primary growth drivers for the Paints and Wallpaper segment. Building Materials include lumber, flooring, tiles, cement, insulation, and drywall.

 

Access the Sample Report:

https://www.profsharemarketresearch.com/diy-home-improvement-market/

 

By Distribution Channels, the Offline Retail is the market leader with more than 65% revenue generation.

Online and Offline retail are the main Distribution Channels, with Offline Retail constituting the highest market share. The Strong demand is due to consumers’ preference for physical inspection of the texture, colour, durability, and quality of the renovation products. Offline stores allow instant purchase, pickup and Expert Guidance that drives the Offline retail segment growth. Online platforms also show strong growth and are likely to grow at a magnificent CAGR between 2026 and 2032.

 

By End-Users, the Residential usage accounts for the largest share in the DIY Home Improvement Market.

As homeowners are increasingly investing in renovations, aesthetic upgrades, and energy-efficient systems, the Residential End-User segment leads the market. Rising home ownership & renovation trends, especially in the Asia-Pacific region, propel the market growth. Commercial usage is also on the rise as SMEs and startups often prefer DIY to reduce costs. Rental property owners use DIY improvements.

 

North America leads the largest DIY Home Improvement Market share and is projected to grow at the highest Compound Annual Growth Rate (CAGR) between 2026 and 2032.

Regional outlook focuses on the market revenue and latest developments in the various regions like North America, Europe, Asia-Pacific, the Middle East, South America and Africa. According to the latest study by Profshare Market Research on the DIY Home Improvement Market, North America holds the largest market share and continues to do so due to the Strong home ownership rates and frequent renovations, along with Widespread availability of DIY workshops, tutorials, and kits. The European DIY Home Improvement Market is driven by the Deep-rooted DIY tradition supported by cultural preference for home personalisation. Asia-Pacific, the Middle-East and South America regions are also projected to show a moderate growth rate due to large population and rising disposable income.

 

Major Key Players in the DIY Home Improvement Market:

  • Amazon
  • Walmart
  • Ace Hardware
  • Home Depot Inc.
  • Flipkart
  • Kesko corporation
  • Kingfisher Plc

 

DIY Home Improvement Market Report Key Takeaways:

  • The DIY Home Improvement Market is projected to reach USD 1173990 million by the end of 2032, with an approximate CAGR of 4.5 % between 2026 and 2032.

 

  • By market dynamics, the Rising Renovation Demand, Growing Homeownership, Technological advancement and Digitalization are the important growth factors for the DIY Home Improvement Market.

 

  • Based on the Product types, the Paints and Wallpaper segment is projected to grow at the highest CAGR during the forecast period. Low cost, minimal skill, and quick results propel the segment growth.

 

  • By Distribution Channels, the Offline Retail is projected to grow at the highest CAGR during the forecast period due to consumers’ preference for physical touch, instant purchase andExpert advice.

 

  • The End-User analysis estimates that the Residential End-User segment is the market leader because of the growing investment in renovations and aesthetic upgrades.

 

  • Based on the regional analysis, the North America region is estimated to hold the largest market share due to the Rising Renovation Demand, Growing Homeownership, Technological advancement and Digitalization.

 

  • According to Key Players Insight, the core technology DIY Home Improvement market is semi-saturated, with opportunities for manufactuers in innovation, cosumer preference and emerging economies.

 

Industry Top Reports:

 

Green Building Materials Market: Green Building Materials Market by Product Types ( Sealant, Concrete admixture, Grouting and Flooring, Coatings) by Applications ( Roofing, Exterior siding, Framing, Insulation), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032.

 

Carpets & Rugs Market: Global Carpets & Rugs Market by Product Type (Nylon, Polyester, Polypropylene) by Application /End User(Residential, Non-residential, Automotive & transportation), Regional Outlook (North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032.

 

Solar Rooftop Market: Solar Rooftop Market by Grid Type (On-Grid Type, Off-Grid Type, Grid-interactive, Hybrid) by Application / End User (Commercial, Industrial, Residential, Energy Consumers), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032.

 

Solar Control Films Market: Solar Control Films Market by Visibility Type (Clear, Dyed, Vacuum Coated) by Reflective Nature (Non-Reflective, Reflective) by Application /End User (Interior designing, Automotive, Construction, Marine, Hospitals), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032.

 

About Proshare Market Research

Profshare Market Research is a leading Market Research & Consulting Organization that turns data into decisions and insights into impact. We are a global market intelligence firm committed to delivering actionable, accurate, and forward-looking market research that empowers businesses to stay ahead in an ever-changing marketplace.

From emerging startups to Fortune 500 companies, our clients trust us to decode complexity, spot opportunities, and reduce risk. With a robust network of data analysts and industry experts, we provide customized market research solutions that align with clients’ unique goals.

Media Contact
Company Name: Profshare Market Research
Contact Person: Rajeswari Deep
Email: Send Email
Phone: + 1 628 8006808
Address:1207 Delaware Ave. Suite 4458 DE 19806
City: Wilmington
State: Delaware
Country: United States
Website: https://www.profsharemarketresearch.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rising Trend of Self-Reliant Renovations Fuels Global DIY Home Improvement Market Growth- Profshare Market Research

Global Intrusion Detection and Prevention System (IDPS) Market Accelerates Amid Rising Adoption of Cloud and AI-Driven Security Platforms

“Intrusion Detection and Prevention System (IDPS) Market Size and Forecast 2032”
Intrusion Detection and Prevention System (IDPS) Market is estimated to reach USD 16792.56 million by 2032 with a Compound Annual Growth Rate (CAGR) of 11 % from 2026 to 2032. Rising Cybersecurity concerns and large investments by organizations in online security are the primary growth drivers of the IDPS Market.

The latest premium report by Profshare Market Research, “Intrusion Detection and Prevention System (IDPS) Market by Types (Solutions, Services) by Applications (BFSI (Banking, Financial Services & Insurance), Government, IT and Telecom, Health, Utilities, Education Institutes) by Deployment Types (On-premise, Cloud-based and Hybrid and Forecast 2026-2032”

 

Intrusion Detection and Prevention System (IDPS) Market Segmentation:

By Component types, the Solutions segment is projected to show the highest CAGR during the forecast period.

Solutions, Services, and Hardware are primary Component types, and the Solutions segment leads the market due to high demand for integration of AI/ML-based detection, behaviour analytics, and improvements in network security by the enterprises. APIs + threat intel feeds are now integrated into platforms for real-time updates, further propelling solution segments’ growth. The service segment is also estimated to show strong growth, mainly attributed to outsourcing 24/7 monitoring, advanced threat hunting, and incident response.

 

Access the Sample Report:

https://www.profsharemarketresearch.com/intrusion-detection-and-prevention-system-idps-market/

 

By Deployment types, the On-premise Deployment is projected to show the highest CAGR during the forecast period.

On-premise, Cloud-based and Hybrid are the main Deployment types, and the On-premise IDPS Deployment generates the highest revenue and continues to grow strongly in the upcoming years. Growth rate for cloud-based deployment is highest due to Rapid cloud adoption, distributed workforces, cloud-native applications, and the need to protect cloud workloads. A balance between On-premise and Cloud-based security is achieved through the Hybrid IDPS deployments, as it delivers consistent security performance across both environments.

 

By Application, the BFSI (Banking, Financial Services & Insurance) application accounts for the largest share in the Intrusion Detection and Prevention System (IDPS) Market.

BFSI, Government, IT and Telecom, Health, Utilities, Education Institutes are the primary applications analysed in the report. Growthwise IDPS application registered the highest CAGR between 2020 and 2025 and is expected to lead the market during the forecast period. Fraud, phishing, ransomware, and advanced persistent threats (APTs) are more consistent in the BFSI sector than in any other, and hence, efficient cybersecurity deployments are very critical. IT service providers integrate IDPS into their data centres and managed security offerings; the segment is projected to show strong growth in the upcoming years.

 

North America holds the largest Intrusion Detection and Prevention System (IDPS) Market share and is projected to grow at the highest Compound Annual Growth Rate (CAGR) between 2026 and 2032.

Regional outlook focuses on the market revenue and latest developments in the various regions like North America, Europe, Asia-Pacific, the Middle East, South America and Africa. According to the latest study by Profshare Market Research on the Intrusion Detection and Prevention System (IDPS) Market, North America holds the largest market share and continues to do so due to the Presence of leading vendors like Cisco, Palo Alto, IBM, Fortinet, Juniper, along with an established cybersecurity infrastructure. Asia-Pacific is the second largest market, while Europe, the Middle East, South America and Africa are also anticipated to generate significant revenue during the forecast period.

 

Major Key Players in the Intrusion Detection and Prevention System (IDPS) Market:

  • Cisco
  • IBM
  • Check Point
  • HP
  • Netscout
  • AirWave (Aruba)
  • Extreme Networks
  • Fortinet
  • ForeScout
  • WatchGuard
  • Venustech
  • Topsec
  • Qihoo 360

 

Intrusion Detection and Prevention System (IDPS) Market Report Key Takeaways

  • The Intrusion Detection and Prevention System (IDPS) Market is projected to reach USD 16792.56 million by the end of 2032, with an approximate CAGR of 11 % between 2026 and 2032.

 

  • By market dynamics, the Rising Cybersecurity concerns and large investments by organizations in online security are the main growth drivers for the Intrusion Detection and Prevention System (IDPS) Market.

 

  • Based on the Component types, the Solutions segment is projected to grow at the highest CAGR during the forecast period. High demand for integration of AI/ML-based detection and behaviour analytics drives the segment growth.

 

  • By Deployment types, the On-premise Deployment is projected to grow at the highest CAGR during the forecast period due to Rapid cloud adoption, distributed workforces, and cloud-native applications.

 

  • The application market study shows that the BFSI (Banking, Financial Services & Insurance) application dominates the market, as Fraud, phishing, ransomware, and advanced persistent threats (APTs) are very common in this sector.

 

  • Based on the regional analysis, the North America region is estimated to hold the largest market share due to the Presence of leading vendors and a mature market.

 

  • By Key Players Insight, the core technology Intrusion Detection and Prevention System (IDPS) market is saturated, but cloud, hybrid and AI/ML-based deployment markets hold greater potential between 2026 and 2032.

 

Industry Top Reports:

Data-Loss Prevention (DLP) Market: Data-Loss Prevention (DLP) Market by Product Types ( Network DLP, Data Centre/Storage DLP, Endpoint DLP) by End User ( IT and Telecommunication, Healthcare, BFSI, Retail and Logistics, Manufacturing, Government, Others), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032.

 

Cybersecurity Market: Cybersecurity Market by Solutions ( Cloud Security, Data Loss Prevention (DLP), Intrusion Prevention Systems (IPS), Identity and Access Management (IAM), Antivirus/anti-malware, Secure Web Gateway, Network Security) by Application ( Government, BFSI, IT and Telecommunication, Manufacturing, Healthcare, Other), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032.

 

Real Time Locating Systems (RTLS) Market: Real Time Locating Systems (RTLS) Market Report by Technology Type ( Wi-Fi Type, Wireless Type, Wired Type) by Application (Hospitals, Manufacturing and Supply Chain Management, Chemicals and Dangerous Goods Industry, Mining Industry, Government and the Army, Amusement Park, Agriculture, Transportation), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032.

 

Telecom Analytics Market: Market Segmentation (Servers, Storage, Network Equipment, Sales and Marketing Management, Customer Management, Risk and Compliance Management), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032.

 

About Proshare Market Research

Profshare Market Research is a leading Market Research & Consulting Organization that turns data into decisions and insights into impact. We are a global market intelligence firm committed to delivering actionable, accurate, and forward-looking market research that empowers businesses to stay ahead in an ever-changing marketplace.

From emerging startups to Fortune 500 companies, our clients trust us to decode complexity, spot opportunities, and reduce risk. With a robust network of data analysts and industry experts, we provide customized market research solutions that align with clients’ unique goals.

Media Contact
Company Name: Profshare Market Research
Contact Person: Rajeswari Deep
Email: Send Email
Phone: + 1 628 8006808
Address:1207 Delaware Ave. Suite 4458 DE 19806
City: Wilmington
State: Delaware
Country: United States
Website: https://www.profsharemarketresearch.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global Intrusion Detection and Prevention System (IDPS) Market Accelerates Amid Rising Adoption of Cloud and AI-Driven Security Platforms